Patents by Inventor Mohammed A. Kashem

Mohammed A. Kashem has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Modified sialyl Lewis.sup.x compounds
    Patent number: 5939290
    Abstract: The present invention is drawn to methods for the synthesis of sialyl Lewis.sup.x derivatives modified at the C-2 and/or C-6 position of GlcNAc employing chemoenzymatic synthesis. The derivatives find use in the treatment and prevention of diseases.
    Type: Grant
    Filed: May 19, 1995
    Date of Patent: August 17, 1999
    Assignee: Alberta Research Council
    Inventors: Andre P. Venot, Pandurang V. Nikrad, Mohammed A. Kashem
  • Modified sialyl Lewis.sup.a compounds
    Patent number: 5882901
    Abstract: The present invention is drawn to methods for the synthesis of Lewis.sup.a derivatives modified at the C-2 and/or C-6 position of GlcNAc employing chemo-enzymatic synthesis. The derivatives find use in the treatment and prevention of diseases.
    Type: Grant
    Filed: May 26, 1995
    Date of Patent: March 16, 1999
    Assignee: Alberta Research Council
    Inventors: Andre P. Venot, Pandurang V. Nikrad, Mohammed A. Kashem
  • Modified sialyl Lewis.sup.a compounds
    Patent number: 5872096
    Abstract: The present invention is drawn to methods for the synthesis of Lewis.sup.a derivatives modified at the C-2 and/or C-6 position of GlcNAc employing chemo-enzymatic synthesis. The derivatives find use in the treatment and prevention of diseases.
    Type: Grant
    Filed: October 20, 1994
    Date of Patent: February 16, 1999
    Assignee: Alberta Research Council
    Inventors: Andre P. Venot, Pandurang V. Nikrad, Mohammed A. Kashem
  • Modified sialyl Lewis.sup.x compounds
    Patent number: 5759993
    Abstract: The present invention is drawn to methods for the synthesis of sialyl Lewis.sup.x derivatives modified at the C-2 and/or C-6 position of GlcNAc employing chemo-enzymatic synthesis. The derivatives find use in the treatment and prevention of diseases.
    Type: Grant
    Filed: October 20, 1994
    Date of Patent: June 2, 1998
    Assignee: Alberta Research Council
    Inventors: Andre P. Venot, Pandurang V. Nikrad, Mohammed A. Kashem
  • Time dependent administration of oligosaccharide glycosides related to blood group determinants having a type I or type II core structure in reducing inflammation in a sensitized mammal arising form exposure to an antigen
    Patent number: 5646123
    Abstract: Disclosed are methods for reducing the degree of antigen induced inflammation in a sensitized mammals. The disclosed methods employ oligosaccharide glycosides related to blood group determinants having a type I or type II core structure wherein the administration of such oligosaccharide glycosides is after initiation of the mammal's immune response but at or prior one-half the period of time required to effect maximal antigen-induced inflammation.
    Type: Grant
    Filed: March 17, 1995
    Date of Patent: July 8, 1997
    Assignee: Alberta Research Council
    Inventors: Robert M. Ippolito, Wasimul Haque, Cong Jiang, H. Rizk Hanna, Andre P. Venot, Pandurang V. Nikrad, Mohammed A. Kashem, Richard Smith, Om P. Srivastava
  • Immunosuppressive and tolerogenic modified Lewis.sup.x compounds
    Patent number: 5580858
    Abstract: Disclosed are novel Lewis.sup.x and Lewis.sup.a analogues, pharmaceutical compositions containing such analogues, methods for their preparation and methods for their use.
    Type: Grant
    Filed: November 4, 1994
    Date of Patent: December 3, 1996
    Assignee: Alberta Research Council
    Inventors: Robert M. Ippolito, Wasimul Haque, Cong Jiang, H. Rizk Hanna, Andre P. Venot, Pandurang V. Nikrad, Mohammed A. Kashem, Richard H. Smith
  • Methods for the synthesis of monofucosylated oligosaccharides terminating in di-N-acetyllactosaminyl structures
    Patent number: 5550155
    Abstract: Monofucosylated and monosialyated derivatives of the compound .beta.Gal(1-4).beta.GlcNAc(1-3).beta.Gal(1-4).beta.GlcNAc-OR, where R is hydrogen, a saccharide, an oligosaccharide or an aglycon moiety have been found to be useful in modulating a cell-mediated immune inflammatory response in mammals.
    Type: Grant
    Filed: October 14, 1994
    Date of Patent: August 27, 1996
    Assignee: Alberta Research Council
    Inventors: Mohammed A. Kashem, Andre P. Venot, Richard Smith
  • Methods for the synthesis of monofucosylated oligosaccharides terminating in di-N-acetyllactosaminyl structures
    Patent number: 5374655
    Abstract: Disclosed are methods for the preparation of monofucosylated and sialylated derivatives of the compound .beta.Gal(1-4).beta.GlcNAc(1-3).beta.Gal(1-4).beta.GlcNAc-OR. In particular, the methods of this invention provide for a multi-step synthesis wherein selective monofucosylation is accomplished on the 3-hydroxy group on only one of the GlcNAc units found in the .beta.Gal(1-4) .beta.GlcNAc (1-3) .beta.Gal (1-4) .beta.GlcNAc-OR compound. In this step, monofucosylation is achieved by use of the .alpha.(1-3)fucosyltransferase.
    Type: Grant
    Filed: July 14, 1992
    Date of Patent: December 20, 1994
    Assignee: Alberta Research Council
    Inventors: Mohammed Kashem, Andre P. Venot, Richard Smith
  • Methods for the enzymatic synthesis of alpha-sialylated oligosaccharide glycosides
    Patent number: 5352670
    Abstract: Disclosed are methods for the enzymatic synthesis of alpha-sialylated oligosaccharide glycosides. Specifically, in the disclosed methods, sialyltransferase is activated to transfer an analogue of sialic acid, employed as its CMP-nucleotide derivative, to an oligosaccharide glycoside. The analogue of sialic acid and the oligosaccharide employed in this method are selected to be compatible with the sialyltransferase employed.
    Type: Grant
    Filed: October 2, 1991
    Date of Patent: October 4, 1994
    Assignee: Alberta Research Council
    Inventors: Andre P. Venot, Frank M. Unger, Mohammed A. Kashem, Paul Bird, M. Abdul Mazid
  • Process for the separation and purification of sialyl transferases
    Patent number: 5059535
    Abstract: Specific sialyl transferases (ST) are important enzymes in the manufacture of carbohydrate moieties useful for pharmacological purposes and for diagnostic and clinical procedures. The invention offers simplified methods to isolate highly specific forms of these ST enzymes by taking advantage of the affinity of the ST for its acceptor substrate in the presence of the sialyl-CMP analogs, such as CDP. Specifically exemplified are isolation of the alpha 2,3-ST, specific for Le.sup.c or LacNAc, and alpha 2,6-ST specific for LacNAc.
    Type: Grant
    Filed: April 12, 1989
    Date of Patent: October 22, 1991
    Assignee: Chembiomed, Ltd.
    Inventors: M. Abdul Mazid, Mohammed A. Kashem